Shaqfah J, Kang W, Gaudette F, Khalil M, Kwan C, Belliveau S
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39841218
DOI: 10.1007/s00210-024-03627-1.
Rodriguez-Oroz M, Martinez-Fernandez R, Lipsman N, Horisawa S, Moro E
Mov Disord. 2024; 40(2):231-240.
PMID: 39726415
PMC: 11832798.
DOI: 10.1002/mds.30090.
Ciarrocchi D, Pecoraro P, Zompanti A, Pennazza G, Santonico M, di Biase L
J Clin Med. 2024; 13(23).
PMID: 39685917
PMC: 11641839.
DOI: 10.3390/jcm13237458.
Olaoye O, Aksoy A, Hyytiainen S, Narits A, Hickey M
Biology (Basel). 2024; 13(11).
PMID: 39596848
PMC: 11591693.
DOI: 10.3390/biology13110893.
Twedell E, Bair-Marshall C, Girasole A, Scaria L, Sridhar S, Nelson A
bioRxiv. 2024; .
PMID: 39416118
PMC: 11482940.
DOI: 10.1101/2024.10.11.617939.
Dopamine dynamics are dispensable for movement but promote reward responses.
Cai X, Liu C, Tsutsui-Kimura I, Lee J, Guo C, Banerjee A
Nature. 2024; 635(8038):406-414.
PMID: 39415006
PMC: 11718420.
DOI: 10.1038/s41586-024-08038-z.
The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications.
Banks W, Rhea E, Reed M, Erickson M
Cell Rep Med. 2024; 5(11):101760.
PMID: 39383873
PMC: 11604479.
DOI: 10.1016/j.xcrm.2024.101760.
Movement-related activity in the internal globus pallidus of the parkinsonian macaque.
Kase D, Zimnik A, Han Y, Harsch D, Bacha S, Cox K
bioRxiv. 2024; .
PMID: 39257740
PMC: 11383679.
DOI: 10.1101/2024.08.29.610310.
Construct, Face, and Predictive Validity of Parkinson's Disease Rodent Models.
Guimaraes R, Resende M, Tavares M, Belardinelli de Azevedo C, Ruiz M, Mortari M
Int J Mol Sci. 2024; 25(16).
PMID: 39201659
PMC: 11354451.
DOI: 10.3390/ijms25168971.
Lipids and α-Synuclein: adding further variables to the equation.
Schepers J, Loser T, Behl C
Front Mol Biosci. 2024; 11:1455817.
PMID: 39188788
PMC: 11345258.
DOI: 10.3389/fmolb.2024.1455817.
L-DOPA Autoxidation: An Empirical Valence Bond Simulation of the Reactive Step.
Prah A, Mavri J
J Phys Chem B. 2024; 128(35):8355-8361.
PMID: 39180475
PMC: 11382278.
DOI: 10.1021/acs.jpcb.4c03002.
Revolutionizing our understanding of Parkinson's disease: Dr. Heinz Reichmann's pioneering research and future research direction.
Tanaka M, Vecsei L
J Neural Transm (Vienna). 2024; 131(12):1367-1387.
PMID: 39110245
PMC: 11608389.
DOI: 10.1007/s00702-024-02812-z.
Synthesis, Crystal Structure, Hirshfeld Surface Analysis, and Computational Approach of a New Pyrazolo[3,4-]isoquinoline Derivative as Potent against Leucine-Rich Repeat Kinase 2 (LRRK2).
Bakhite E, Mohamed S, Lai C, Subramani K, Marae I, Abuelhassan S
ACS Omega. 2024; 9(28):30751-30770.
PMID: 39035914
PMC: 11256088.
DOI: 10.1021/acsomega.4c03208.
A Computational Model of Deep Brain Stimulation for Parkinson's Disease Tremor and Bradykinesia.
Nair S, Chakravarthy S
Brain Sci. 2024; 14(6).
PMID: 38928620
PMC: 11201485.
DOI: 10.3390/brainsci14060620.
Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Chen Y, Kuo T, Wang V, Cheng P, Yi-Kung Huang E, Ma K
J Parkinsons Dis. 2024; 14(5):941-964.
PMID: 38905058
PMC: 11307072.
DOI: 10.3233/JPD-240080.
Impact of Physical Exercise on Levodopa Therapy Across Parkinson's Disease Stages.
Figura M, Mrozowicz A, Milanowski L, Szlufik S, Rackowska E, Lypkan H
J Parkinsons Dis. 2024; 14(5):1039-1049.
PMID: 38905055
PMC: 11307027.
DOI: 10.3233/JPD-230384.
Exploring the multifaceted role of RASGRP1 in disease: immune, neural, metabolic, and oncogenic perspectives.
Fan S, Kang B, Li S, Li W, Chen C, Chen J
Cell Cycle. 2024; 23(6):722-746.
PMID: 38865342
PMC: 11229727.
DOI: 10.1080/15384101.2024.2366009.
Implication of regional selectivity of dopamine deficits in impaired suppressing of involuntary movements in Parkinson's disease.
Lee H, Kim H, Hikosaka O
Neurosci Biobehav Rev. 2024; 162:105719.
PMID: 38759470
PMC: 11167649.
DOI: 10.1016/j.neubiorev.2024.105719.
Protective Effect of Resveratrol Combined with Levodopa Against Oxidative Damage in Dopaminergic Neurons.
Zhang Y, Guo H, Fu H
Cell Biochem Biophys. 2024; 82(2):817-826.
PMID: 38619644
DOI: 10.1007/s12013-024-01233-9.
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.
Savaryn J, Smith R, Rosebraugh M, Neenan M, Burton R, Marsh K
Pharmacol Res Perspect. 2024; 12(2):e1190.
PMID: 38597598
PMC: 11005717.
DOI: 10.1002/prp2.1190.
